Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?
Annu Rev Neurosci. 2016 Feb 24. Epub 2016 Feb 24. PMID: 27023732
Natalie E Zlebnik
The Cannabis sativa plant has been used to treat various physiological and psychiatric conditions for millennia. Current research is focused on isolating potentially therapeutic chemical constituents from the plant for use in the treatment of many central nervous system disorders. Of particular interest is the primary nonpsychoactive constituent cannabidiol (CBD). UnlikeΔ9-tetrahydrocannabinol (THC), CBD does not act through the cannabinoid type 1 (CB1) receptor but has many other receptor targets that may play a role in psychiatric disorders. Here we review preclinical and clinical data outlining the therapeutic efficacy of CBD for the treatment of motivational disorders such as drug addiction, anxiety, and depression. Across studies, findings suggest promising treatment effects and potentially overlapping mechanisms of action for CBD in these disorders and indicate the need for further systematic investigation of the viability of CBD as a psychiatric pharmacotherapy. Expected final online publication date for the Annual Review of Neuroscience Volume 39 is July 08, 2016. Please see https://www.annualreviews.org/catalog/pubdates.aspx for revised estimates.